|
Needs Assessment
Through needs assessment surveys, literature searches, advisory
board suggestions, and recent specialty publications, ImproMED
has identified that a need exists to educate ophthalmologists
on recent advances in glaucoma treatment. Specifically,
recently published results from the Ocular Hypertension
Treatment Study show that treatment is effective in delaying
or preventing glaucomatous optic disc and/or visual field
loss. These results provide evidence to support reconsideration
of current glaucoma treatment practices.
Target Audience
This activity is intended for general ophthalmologists and
those with a subspecialty in Glaucoma.
Overall Purpose
The purpose of this activity is to expand dissemination
of the Ocular Hypertension Treatment Study results to date
and to help participants understand the practical implications
of the study.
Educational Objectives
Upon completion of this CME activity, participants should
have increased overall skills, knowledge, attitudes, and
performance, with a specific ability to:
Skill(s)
Develop appropriate treatment plans for patients with
ocular hypertension at moderate to high risk of glaucoma,
considering risk:benefit ratios of therapy
Knowledge
Identify baseline demographic and clinical factors that
help predict which patients are likely to develop primary
open-angle glaucoma
Attitude(s)
Recognize the value of measuring corneal thickness in
all patients with ocular hypertension or glaucoma
Performance
Translate key messages of the Ocular Hypertension Treatment
Study into practical applications to improve patient health
outcomes.
Designation of Credit Statement
ImproMED designates this educational activity for a maximum
of 1.0 category 1 credit toward the AMA Physician’s
Recognition Award. Each physician should claim only those
credits that he/she actually spent in the activity.
Disclosure Policy
It is the policy of ImproMED to ensure balance, independence,
objectivity, and scientific rigor in all its sponsored educational
activities. All faculty are expected to disclose to program
audiences any significant relationships related to the content
of their presentations.
Unapproved uses of drug regimens may be discussed.
 Activity
Review Committee
This activity was reviewed by Richard
K. Parrish II, MD, Activity Chair,
James Spindler, MD, and Suzanne
Eggers.
Term
of Approval: May 2003 through May 2004.
The certification periods for the following activities have expired, but the programs remain available for viewing. Please note that your participation in these activities is not eligible for AMA PRA category 1 credit, but may be eligible for AMA PRA category 2 credit. Please contact ImproMED with questions (seggers@impromed.org or 269.329.0651 x31) or view the AMA guidelines for PRA credit at http://www.ama-assn.org/ama/pub/category/2938.html.
|
